What to Expect From Zoetis' Q3 2025 Earnings Report

Core Insights - Zoetis Inc. is a global leader in animal health with a market cap of $64.3 billion, focusing on medicines, vaccines, diagnostics, and precision health products for livestock and companion animals [1] Financial Performance - The company is expected to announce fiscal Q3 2025 results on Nov. 4, with analysts predicting an adjusted EPS of $1.62, a 2.5% increase from $1.58 in the same quarter last year [2] - For fiscal 2025, adjusted EPS is projected to be $6.35, reflecting a 7.3% rise from $5.92 in fiscal 2024, with further growth anticipated to $6.87 in fiscal 2026, an 8.2% year-over-year increase [3] Stock Performance - Over the past 52 weeks, Zoetis shares have declined by 22.9%, underperforming the S&P 500 Index, which increased by 15.3%, and the Health Care Select Sector SPDR Fund, which saw a 4.1% decline [4] - Despite reporting better-than-expected Q2 2025 adjusted EPS of $1.76 and revenue of $2.5 billion, shares fell by 3.8% due to weaknesses in certain product lines, including a 21% drop in U.S. livestock product sales [5] Analyst Ratings - The consensus rating for Zoetis stock is bullish, with a "Strong Buy" rating from 11 out of 16 analysts, one "Moderate Buy," and four "Hold" ratings. The average price target is $192.50, indicating a potential upside of 31.2% from current levels [6]